Dare Bioscience Inc

NASDAQ:DARE   11:05:03 AM EDT
1.09
+0.01 (+0.93%)
Earnings Announcements

Dare Bioscience Reports 2021 Results

Published: 03/31/2022 12:57 GMT
Dare Bioscience Inc (DARE) - DarÉ Bioscience Reports Full-year 2021 Financial Results and Provides a Company Update.
Dare Bioscience Inc - U.S. Commercial Launch of Xaciato Expected in 4q-2022.
Dare Bioscience Inc - Cash and Cash Equivalents: $51.7 Million at December 31, 2021, Compared to $4.7 Million at December 31, 2020.
Revenue is expected to be $5.38 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0.35 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.